BIOLOGICAL · Unmapped registry intervention
Ipilimumab
Find medicine records ·
Find other trials using this name
Clinical trial
Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted
NCT04185311
Drugs and interventions used in this trial
3 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
BIOLOGICAL · Unmapped registry intervention
Nivolumab
Find medicine records ·
Find other trials using this name
BIOLOGICAL · Unmapped registry intervention
Talimogene Laherparepvec
Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedIpilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted
Design: INTERVENTIONAL · Status: TERMINATED · Phase: PHASE1
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Anatomic Stage 0 Breast Cancer AJCC v8unresolved
Anatomic Stage I Breast Cancer AJCC v8unresolved
Anatomic Stage IA Breast Cancer AJCC v8unresolved
Anatomic Stage IB Breast Cancer AJCC v8unresolved
Anatomic Stage II Breast Cancer AJCC v8unresolved
Anatomic Stage IIA Breast Cancer AJCC v8unresolved
Anatomic Stage IIB Breast Cancer AJCC v8unresolved
HER2/Neu Negativeunresolved
Progesterone Receptor Negativeunresolved
Prognostic Stage 0 Breast Cancer AJCC v8unresolved
Prognostic Stage I Breast Cancer AJCC v8unresolved
Interventions
Sponsors & collaborators
Jonsson Comprehensive Cancer Centerlead sponsor
National Cancer Institute (NCI)collaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT04185311 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.